In the United States<unk>  is indicated for the treatment of people with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options. It is also indicated to treat HABP/VABP in adults 18 years of age and older. In the European Union it is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
Imipenem/cilastatin/relebactam
Meropenem/vaborbactam
Ceftazidime/avibactam
Teicoplanin
Resistin
Neomycin/polymyxin B/bacitracin
Fosfomycin/tobramycin
Meropenem